What Is Milo Biotechnology?

Milo Biotechnology is company developing a therapy that increases muscle strength or decrease the rate of muscle atrophy for the treatment of muscular disorders.

The company’s technology, a gene therapy-based up-regulation of the muscle-strengthening follistatin protein, was developed at and is exclusively licensed from Nationwide Children’s Hospital (Ohio, U.S.A.).

In 2014 the therapy completed a Phase I/II clinical study in Becker Muscular Dystrophy establishing initial safety and efficacy.

Recent News

10Nov

The Duchenne Alliance commits $500,000 to Dr. Jerry Mendell and Milo Biotechnology to fund first Duchenne Follistatin Gene Therapy Trial

0 Comments
Columbus and Cleveland, OH, November 10, 2014– The International Duchenne Alliance announced today that it will allocate $500,000 to Dr.... Read More →
20Oct

Milo Biotechnology’s Follistatin Gene Therapy Increases Function in Becker Muscular Dystrophy Patients

0 Comments
Data published today in the journal Molecular Therapy demonstrates initial clinical proof of principle of a gene therapy to increase... Read More →
Back to Top